糖皮质激素使用与念珠菌血症:全国性病例对照研究
OBJECTIVES: Glucocorticoids are widely used for acute and chronic diseases. Although their association with increased infection risk is well-established, population-level data on glucocorticoid use and candidemia are limited.…
要点
- 口服糖皮质激素暴露与念珠菌血症风险升高独立相关(aOR 2.17)。
- 风险呈剂量依赖:>1500 mg泼尼松等效剂量者aOR达5.23。
- 炎症性肠病和风湿病患者中关联最强,需加强监测。
核心结论
- 糖皮质激素使用与念珠菌血症风险升高相关,且呈明确剂量依赖关系。
- 该关联在常见念珠菌种中一致,在炎症性肠病、风湿病和慢性肺病患者中最显著。
研究设计与样本
- 全国性注册登记病例对照研究,纳入2010-2024年丹麦所有首次念珠菌血流感染成人。
主要发现
- 糖皮质激素暴露与念珠菌血症总体风险升高相关(aOR 2.17,95%CI 1.92-2.45)。
- 白念珠菌aOR 2.22(95%CI 1.86-2.65),光滑念珠菌aOR 2.08(95%CI 1.70-2.55),热带念珠菌aOR 2.22(95%CI 1.22-4.04),克柔念珠菌aOR 2.38(95%CI 1.26-4.48),近平滑念珠菌aOR 2.80(95%CI 1.62-4.85),都柏林念珠菌aOR 1.45(95%CI 0.68-3.09)。
- 累积剂量与风险增加相关:<750 mg组aOR 1.59(95%CI 1.35-1.86),750-1500 mg组aOR 2.25(95%CI 1.75-2.90),>1500 mg组aOR 5.23(95%CI 4.01-6.83)。
- 炎症性肠病患者aOR 4.62(95%CI 2.21-9.43),风湿病患者aOR 3.15(95%CI 2.28-4.35),慢性肺病患者aOR 2.07(95%CI 1.67-2.56)。
关键数值与推荐
- 糖皮质激素暴露定义为索引日期前90天内配取口服糖皮质激素处方。
- 按90天泼尼松等效累积剂量分层:<750 mg、750-1500 mg、>1500 mg。
- 采用条件logistic回归估计调整比值比(aOR)及95%置信区间。
临床怎么用
- 对接受口服糖皮质激素治疗的患者,尤其炎症性肠病、风湿病和慢性肺病患者,应警惕念珠菌血症风险。
- 累积剂量>1500 mg泼尼松等效剂量者风险显著升高,需加强监测和预防意识。
局限性
- 原文摘要未报告具体局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Glucocorticoids are widely used for acute and chronic diseases. Although their association with increased infection risk is well-established, population-level data on glucocorticoid use and candidemia are limited. We investigated the association between oral glucocorticoid exposure and candidemia in a population-based setting over 14 years, with attention to variation by dose, Candida species and underlying disease. METHODS: We conducted a nationwide, registry-based case-control study (2010-2024) including all Danish adults with a first-time Candida bloodstream infection (cases), matched to ten population controls. Glucocorticoid use was defined as redemption of an oral glucocorticoid prescription within 90 days before the index date, categorized by 90-day prednisolone-equivalent cumulative dose. Adjusted odds ratios (aORs) with 95% CIs were estimated using conditional logistic regression. Subgroup analyses evaluated variation by species and underlying conditions. RESULTS: We included 6179 cases and 61 790 controls. Glucocorticoid use was associated with higher odds of candidemia overall (aOR: 2.17, 95% CI: 1.92-2.45), and across major species groups including C. albicans (aOR: 2.22, 95% CI: 1.86-2.65), C. glabrata (aOR: 2.08, 95% CI: 1.70-2.55), C. tropicalis (aOR: 2.22, 95% CI: 1.22-4.04), C. krusei (aOR: 2.38, 95% CI: 1.26-4.48), C. parapsilosis (aOR: 2.80, 95% CI: 1.62-4.85), but not C. dubliniensis (aOR: 1.45, 95% CI: 0.68-3.09). The odds increased with higher cumulative doses (<750 mg; aOR: 1.59, 95% CI: 1.35-1.86, 750-1500 mg; aOR: 2.25, 95% CI: 1.75-2.90, and >1500 mg; aOR: 5.23, 95% CI: 4.01-6.83, compared to nonusers). The highest odds were observed among patients with inflammatory bowel disease (aOR: 4.62, 95% CI: 2.21-9.43), followed by rheumatic disease (aOR: 3.15, 95% CI: 2.28-4.35), and chronic pulmonary disease (aOR: 2.07, 95% CI: 1.67-2.56). CONCLUSION: Glucocorticoid use is associated with increased candidemia odds with a clear dose-dependent relationship, consistent across common Candida species, and most pronounced in inflammatory bowel disease, rheumatic disease, and chronic pulmonary disease.
引用
- Leding C, Meddis A, Holler JG, et al. Glucocorticoid use and candidemia: results from a nationwide case-control study. Clin Microbiol Infect. 2026. PMID: 42219031. doi:10.1016/j.cmi.2026.05.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。